Patients still benefit from Eisai and Biogen Alzheimer's drug after four years, study finds

Eisai and Biogen's Alzheimer's drug Leqembi demonstrated sustained efficacy over four years, slowing cognitive decline by 34% in early-stage patients compared to expected progression without treatment, with no new safety issues reported beyond initial side effects. This long-term data reinforces its market position, particularly as an injectable version is under FDA review, with Eisai's chief clinical officer noting "escalating usage" and positive regulatory interactions for the drug.

Analysis

The four-year follow-up data for Leqembi significantly de-risks the long-term commercial profile for partners Eisai and Biogen (BIIB). The study demonstrated that the drug slowed cognitive decline by 34% over the period, a notable improvement on the 27% rate observed over 18 months which underpinned its initial U.S. approval. Crucially, the absence of new safety signals over four years, with adverse events like brain swelling and bleeding largely confined to the initial six months, strengthens the case for sustained patient use. This reinforces management's commentary on "escalating usage" and provides a solid foundation ahead of upcoming quarterly results from both companies. A key near-term catalyst is the FDA's pending decision by August 31 on an injectable formulation; an approval would substantially enhance patient access and convenience, potentially accelerating the revenue ramp. While this data solidifies Leqembi's current market position, the competitive landscape is evolving, with both Eisai and Eli Lilly (LLY) pursuing studies in pre-symptomatic populations, signaling the next phase of competition in Alzheimer's treatment.

Key Decisions for Investors

• Investors holding or considering a position in Biogen (BIIB) should monitor the FDA's decision by August 31 for the injectable version of Leqembi, as an approval represents a significant near-term catalyst for accelerating adoption.
• The positive long-term efficacy and safety data reinforces the fundamental bull case for Leqembi, however, it remains prudent to monitor clinical trial progress from competitor Eli Lilly (LLY) as a key long-term risk factor.
• Pay close attention to management's commentary on the upcoming Biogen and Eisai earnings calls for specific metrics regarding Leqembi's "escalating usage" and the initial commercial ramp, which will provide crucial validation of the drug's market trajectory.